Durability of Nitinol in self-expanding devices Authors: Francesco Nappi, Cristiano Spadaccio Published: 2026 In the recent report by Besola et al. (1), a 73-year-old female patient was referred to the clinic suffering from decompensated heart failure. The procedure performed involved a valve-in-valve surgery using a Medtronic Evolut R 26 mm valve (Medtronic, Minneapolis, MN, USA) to address early structural valve degeneration (SVD) subsequent to the implantation of the Corcym Perceval M valve (Corcym, Milan, Italy). It is important to note that Nitinol (Ni-Ti) is an essential component in the design of the explanted devices. As detailed in the report of the US CoreValve Clinical Investigators, the transcatheter bioprosthesis consists of a self-expanding Ni-Ti frame and a porcine trileaflet pericardial valve produced by Medtronic (MN 55432-5604 USA; https://www.medtronic.com/en-us/index.html) and known as the CoreValve. The Perceval technology is the intellectual property of Corcym S.r.l. The product is a sutureless device which gained approval from the U.S. Food and Drug Administration (FDA) in 2016 and is made from bovine pericardium. The stent frame is similar to that of self-expanding transcatheter aortic valve replacement (TAVR) devices, composed of an elastic Ni-Ti alloy with two rings and nine vertical struts. This product is designed to provide consistent stability and secure positioning for the valve, without the need for any permanent stitching Despite the existence of substantial data on the durability of new bioprostheses (2,3), there remains a paucity of data concerning the durability of devices incorporating both bioprostheses and stents (4). Furthermore, there is a need for research to establish whether structural problems with the stent accelerate SVD. In view of the aforementioned points, this well-presented case report provides essential information on the risk of device durability in patients who have undergone both sutureless aortic valve replacement (Su-AVR) and TAVR. O’Hair and colleagues’ study (2) offers a balanced viewpoint on the long-term effectiveness of TAVR in treating severe aortic valve stenosis. It emphasises TAVR’s capacity to match the durability of recent generations of surgical bioprostheses, which are projected to exceed 17 years (3,4). The findings from pivotal biomechanical studies have led to the use of Ni-Ti in the production of stents, enabling the creation of cutting-edge devices for treating structural valve disease in a new aortic valve replacement procedure. Ni-Ti is a key component in two major medical device applications. First, it is crucial for the self-expanding percutaneous transcatheter aortic valves. Second, it is essential for the sutureless aortic valves (5-7). Technological advances in device design and engineering, coupled with the emergence of research findings affirming the safety of the procedures for low-risk patients, have led to a progressive expansion of the indications for TAVR. This expansion now encompasses lower-risk patients as well as high-risk surgical candidates. These devices are designed to support the valve and maintain its position without the need for permanent sutures, ensuring a secure and durable fit. The stent’s elastic properties enhance its adaptability to the aortic anatomy, facilitating improved compliance with the aortic root systo-diastolic motion. This feature is believed to reduce stress on the leaflets, contributing to enhanced performance and reliability. The implantation technique involves the use of a specialised device to collapse the valve without causing damage. This is followed by carefully lowering the valve into the correct position, after which the prosthesis is deployed. The prosthesis then self-expands to its original diameter, and is stabilised through further balloon expansion (5-7). When focusing on a device’s key features, one might overlook its primary objectives, which are to do no harm while maintaining its integrity. Although loss of device reliability may not result in direct clinical consequences immediately, the possibility for such occurrences may rise over the device’s lifespan. Therefore, durability of the implant is a key consideration in the design process. Failure to maintain adequate durability can have significant consequences, including compromising the effectiveness and safety of the procedure. This is particularly relevant in cases where specialised devices such as Su-AVR or TAVR are crucial to guarantee long-term outcomes. The emergence of new platforms designed to treat structural heart disease is driven by a growing demand within the medical device sector for the development of implantable devices that facilitate minimally invasive approaches. The primary advantage of these devices is that they circumvent the need for more extensive surgical interventions that necessitate full exposure to anatomical structures. For these low-profile application scenarios, Ni-Ti is a preferred material due to its exceptional superelastic characteristics. Three Landmark reports published in the last five years have indicated an escalating global prevalence of cardiovascular disease (8-10). There is an increasing demand for new and innovative treatment options. The development of Ni-Ti devices is a key area of research in this field. This is supported by randomized clinical trials, large observational studies, and systematic reviews that have reported the widespread use of new devices made with this material (11-13). Nonetheless, it is not possible to overengineer lower-profile devices in such a way that they exceed the target durability. As was outlined in the 2019 and 2022 Cardiovascular Implant Durability conferences (14), the durability of cardiovascular devices is determined using the three-legged stand durability test. The first step is to understand the loading requirements of the device. The second step is to create a computational model of these loading conditions. The third step is to perform benchtop fatigue testing. Fatigue testing involves subjecting a material to conditions that generate fluctuating stresses and strains. These conditions can result in cracks or complete fracture after a certain number of fluctuations. As illustrated in Figure 1, this example of a fracture in Ni-Ti demonstrates the range of possibilities. The location of stent fractures in Nitinol. The initial failure sites were identified as being in the central axial region of stents (red arrows) that were subjected to both bending and combined bending-torsional conditions. The severity of the impairment differed between the two conditions (S1, S3–S5). In the second scenario, fractures were found to be restricted to the junctional areas of the stent, with stent S2 displaying a single case of unit detachment (yellow arrows). In contrast, the scenario of combined bending-torsional condition was characterised by multiple fractures, all of which were characterised by unit detachment (S6). Furthermore, it was observed that in instance of combined bending-torsional condition, fractures were not only restricted to the junctional sites but also propagated to the peak regions of the struts. This observation indicates that the torsional load may have been a contributing factor in the observed fracture types. Ni-Ti has become a cornerstone material for contemporary cardiovascular implants because it can deliver self-expansion, conformability, and deliverability in anatomically complex territories. As structural heart interventions continue to expand, particularly in transcatheter valve therapies, durability is no longer a distant engineering consideration: it is increasingly a clinical endpoint that influences lifetime management, reintervention strategy, and the credibility of expanding indications. In parallel, the market has seen rapid iteration with multiple device versions entering practice in short succession, at times outpacing the maturation of long-term evidence for earlier generations. In this setting, clinicians need a more uniform and clinically interpretable way to discuss durability across platforms, rather than relying on fragmented device-specific narratives. Finite element analysis (FEA) is the dominant computational approach used to translate physiologic and anatomic boundary conditions into device-level stress-strain fields. For Ni-Ti implants, the clinical relevance of FEA lies in its ability to estimate cyclic strain amplitudes and mean strains under realistic loading, which are closely linked to fatigue damage and fracture susceptibility over time. This paradigm is well illustrated in the stent domain, where fatigue remains a persistent long-term concern influenced by anatomy, loading, design, and procedural factors, and where computational approaches have been used to connect clinical fracture patterns to mechanistic strain metrics (15-18). The opportunity in structural heart is to elevate similar thinking into a shared durability language for self-expanding valve frames and related platforms, where the stress states of newer generations are not fully understood and where frame deformation, leaflet-frame interaction, and potential performance drift may matter clinically over years. Achieving credible FEA in this space requires accurate three-dimensional geometry (including the zero-pressure state), appropriate physiologic loading, and—critically—material characterization and constitutive descriptions that reflect the processed Ni-Ti used in the specific device, rather than idealized generic properties. In practical clinical terms, FEA-derived maps of cyclic strain “hot spots” and deformation patterns provide a mechanistic bridge to endpoints clinicians recognize—progressive frame distortion, paravalvular leak evolution, altered leaflet coaptation/interaction, and conduction disturbance risk driven by localized chronic loading at the annulus and left ventricle outflow tract. Equally important, by interrogating performance across representative anatomic archetypes (rather than a single “average” geometry), FEA can help clinicians and heart teams anticipate which case types and anatomic features are more likely to push a given platform toward higher mechanical burden, thereby informing prudent device selection, boundary-setting for use, and post-implant surveillance (Figure 2). Depicts the findings of FEA simulations of TAVR in two patients who showed SVD. A comparison was made of the positioning (A, red arrows) and reopening (C, black arrows) of the CoreValve and Sapien devices (on the left and right sides, respectively) with the relevant intraoperative angiograms (B). FEA, finite element analysis; SVD, structural valve degeneration; TAVR, transcatheter aortic valve replacement. For clinicians, the practical point is not that FEA replaces bench testing, imaging, or clinical follow-up; rather, that durability assessment needs a coherent platform in which bench fatigue testing and FEA-derived strain mapping inform one another, enabling consistent definitions and comparable claims across devices. Bench testing remains essential but is resource-intensive and time-limited, especially for Ni-Ti where temperature and rate sensitivities constrain accelerated protocols and where long-cycle requirements can span months. A modeling-enabled framework can help define physiologically relevant test envelopes, interpret fractures in the context of boundary conditions, and relate “pass/fail” outcomes to mechanistic strain hotspots, thereby producing durability statements that are clinically legible and comparable across platforms. Importantly, the field is converging on credibility frameworks—verification, validation, and uncertainty quantification—anchored to a clearly stated context of use and risk analysis, which collectively determine when an FEA prediction is sufficiently reliable to support regulated decisions (19-22). In parallel, data-driven constitutive approaches derived directly from measured responses may improve the fidelity and portability of FEA across different production routes and device variants (23,24). Manufacturing and processing variables (cold work, heat treatment, surface modifications, and pre-strain histories) materially alter fatigue response, reinforcing why a uniform durability definition must explicitly incorporate processed material behavior and deployment-induced deformation. As indications broaden and device iterations accelerate, the structural heart community requires a shared, clinically oriented vocabulary for durability that is comparable across platforms and transparent about uncertainty. A pragmatic path forward is to couple standardized bench fatigue paradigms with credible, context-of-use-anchored FEA, so that strain-based metrics can be translated into durable, regulator-ready claims and, importantly, into clinically meaningful expectations for lifetime valve performance and reintervention risk (19-22,25-27). To the best of our knowledge, no multicentre clinical studies have been carried out in which the long-term durability of Ni-TI cardiovascular devices has been evaluated, nor their effectiveness and safety in patients who received the device for aortic valve replacement using Su-AVR or for TAVR, or in the treatment of peripheral artery disease. It is improbable that such studies will be conducted, due to the necessity of having access to well-organised databases in order to perform biomechanical and fluid dynamics modelling. Consequently, the current assessment of Ni-TI durability is based on biomechanical analysis data from a limited number of patients who have received the device. It is unclear whether asymptomatic patients showing signs of material fatigue in the form of abrasion and delamination, or cracks or complete fracture, should undergo material removal. This scenario is no longer viable and is a major concern when it involves proving the absolute validity of a product and its application in a large population of subjects with cardiovascular diseases. As specific device categories advance further along their development trajectory, it is imperative for our community of scientists, engineers, clinicians and regulatory professionals to cooperate in establishing clear guidelines regarding Ni-Ti durability, safety and effectiveness. This should encompass various aspects such as physiologic circumstances, computational modeling, and physical assessments. For new device types, particularly those designed for patients who may be in better health, more active, and younger, we must challenge the conventional approach of using “normal” loading conditions for 10 years of life. For instance, replacement heart valves have been assessed for clinical application in the United States for over 15 years, and as iliofemoral vein stents and structural heart devices are now employed in younger, fitter patients, thereby possibly mimicking 20–30 years of fatigue cycling in more compliant cardiovascular systems, this approach may be suitable. In order to increase demand for technologies that produce more durable Ni-Ti raw materials, such as customized post-processing of existing varieties, designers must focus on designing for longer implant life spans. In addition, the refinement of sophisticated simulation techniques and the adoption of increasingly comprehensive testing methods will gradually shift the reliance on benchtop fatigue testing as the primary indicator of material resilience. Furthermore, a more profound comprehension of the biomechanical environment, encompassing the long-term progression of these in vivo scenarios, will facilitate the establishment of more precise durability objectives during the device conception and development phases. In our efforts to extend the limits of medical-grade Ni-Ti’s performance, effective communication about its reliability is paramount. This encompasses its analytical, empirical, and computational aspects. This editorial is intended to act as a catalyst, encouraging researchers in the field to improve our understanding of these fundamental topics. In order to ensure the long-term durability of Ni-Ti-based cardiovascular devices without compromising their structural integrity, it is essential to promote research through the publication of original articles and reviews relevant to computational modelling and laboratory testing. These publications should prioritise the biomechanical compatibility and durability of the devices. Supplementary The article’s supplementary files as Available at https://jtd.amegroups.com/article/view/10.21037/jtd-2026-0551/prf